Oncology / Non-Small Cell Lung Cancer
Indication
Non-Small Cell Lung Cancer
Assets addressing this indication.
Total attributable cost
$12.5B
$70,896/patient
Drug spend
$4.8B
$27,138/patient
38% of total cost is drugs
All stages, newly diagnosed (2026 incidence estimate) · US